MAY 19, 2022 1:56 PM PDT

Experimental Drug Shows Promise Against ALS

WRITTEN BY: Annie Lennon

A new experimental drug known as NU-9 may be more effective in treating ALS than existing FDA-approved drugs. The corresponding study was published in Nature

ALS is characterized by fatal paralysis caused by the degeneration of the upper section of motor neurons known as axons, which connect the brain to the spinal cord. For a drug to be effective against ALS, it must thus improve axon outgrowth and health. 

In research published last year, scientists found that NU-9 improved two critical factors that lead to ALS in upper motor neurons: protein misfolding and protein aggregation in cells. They further found that neurons in mouse models resembled healthy controls after 60 days of treatment with NU-9. 

In the present study, the researchers tested NU-9 on mouse models of ALS again, both in combination with FDA-approved drugs for ALS - riluzole or edaravone, and by itself. They also compared these results to mice treated exclusively with these pre-existing drugs.

In doing so, the researchers found that NU-9 was able to lengthen axons in diseased upper motor neurons in mice. They also found that its therapeutic effects were stronger than those of existing FDA-approved drugs when taken alone. However, they noted that a combination treatment of NU-9 and either pre-existing drug produced the most significant results. 

NU-9 is now undergoing animal safety studies to determine dose levels and toxic effects in preparation for clinical trials. Should these prove successful, the researchers hope to start Phase 1 clinical trials in early 2023. 

"It is a long process - possibly 10 to 12 years - to discover and bring a new drug to the market," said Richard B. Silverman, the Patrick G. Ryan/Aon Professor at Northwestern University, and one of the study’s authors, "But this drug has us very excited and hopeful about its possibilities to improve the lives of ALS patients, who have been without hope for so long."


Sources: Nature, Science Daily

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 28, 2022
Genetics & Genomics
A Genetic Cause of Lupus is Identified
APR 28, 2022
A Genetic Cause of Lupus is Identified
Lupus is an autoimmune disease that can impact anyone, but tends to affects women between the ages of 15 and 45. The dis ...
MAY 05, 2022
Drug Discovery & Development
Insulin Nasal Spray Improves Cognitive Outcome for Diabetes Patients
MAY 05, 2022
Insulin Nasal Spray Improves Cognitive Outcome for Diabetes Patients
Diabetes is an increasingly common condition that affects at least 1 in 10 U.S adults. Millions more have prediabetes an ...
MAY 13, 2022
Health & Medicine
Increased Mental Health Risks Linked to High Potency Cannabis Concentrates
MAY 13, 2022
Increased Mental Health Risks Linked to High Potency Cannabis Concentrates
As more states legalize cannabis for medical and recreational purposes, the association between excessive cannabis consu ...
MAY 20, 2022
Drug Discovery & Development
Drug Shows Promise in treating Spinal Cord Injury
MAY 20, 2022
Drug Shows Promise in treating Spinal Cord Injury
A drug developed by AstraZeneca preserves 80% of nerve function following spinal cord compression injury. The correspond ...
JUN 13, 2022
Cancer
Clinical Trial Demonstrates an Amazing 100% Response
JUN 13, 2022
Clinical Trial Demonstrates an Amazing 100% Response
The results of a Clinical Trial for rectal cancer patients published last week in the New England Journal of Medicine co ...
JUN 17, 2022
Cannabis Sciences
Projected Increases in Cannabis Use in States Legalizing Recreational Cannabis
JUN 17, 2022
Projected Increases in Cannabis Use in States Legalizing Recreational Cannabis
A study published in the scientific journal Addiction found that people will be more likely to use cannabis as their sta ...
Loading Comments...